Ozbalak, MuratAkay, Olga MeltemPehlivan, MustafaYildiz, BirolUzay, AntYigenoglu, Tugce NurElverdi, Tugrul2024-04-242024-04-2420212152-26502152-2669https://hdl.handle.net/11468/23185[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessRelapsed And RefractoryHodgkin LymphomaBrentuximab VedotinAutologous Stem Cell TransplantationConsolidationBrentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective StudyBrentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective StudyConference Object21S368S369WOS:000691910500283Q3